Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Wenjun Yu
CONTACT
Lead
Doma Biopharmaceutical（Suzhou）Co., Ltd.
This first-in-human (FIH), multicenter, open-label, dose escalation and dose expansion study is to evaluate the safety, preliminary efficacy and pharmacokinetic (PK) characteristics of DM005 monotherapy in participants with advanced solid tumors. DM005, a bispecific ADC developed using fully human antibodies with a common light chain, which targets c-MET and EGFR. Subjects with solid malignant tumors will be treated with DM005 on Day 1 once Q3W (dose adjustments may be required depending on the safety profile and PK data of each dose
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted